The role of temozolomide in the treatment of aggressive pituitary tumors

Journal of Clinical Neuroscience

Volumn 22, Issue 6, 2015, Pages 923-929

  Liu, James K ^a,b,c   Patel, Jimmy ^b   Eloy, Jean Anderson ^a,b,c  

^a NEUROLOGICAL INSTITUTE OF NEW JERSEY   (United States)

^b RWJ Barnabas Health   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

O6 methylguanine DNA methyltransferase; Pituitary adenoma; Pituitary carcinoma; Temozolomide

Indexed keywords

ALKYLATING AGENT; CABERGOLINE; CAPECITABINE; DACARBAZINE; DEXAMETHASONE; GUANINE; KETOCONAZOLE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METYRAPONE; MITOZOLOMIDE; OCTREOTIDE; PASIREOTIDE; PROTEIN MSH6; TEMOZOLOMIDE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; DNA ADDUCT; DNA DAMAGE; DNA METHYLATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG STRUCTURE; GENE MUTATION; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHUMAN; PITUITARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR RECURRENCE; ADENOMA; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DISEASE COURSE; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; PITUITARY NEOPLASMS;

ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; DACARBAZINE; DISEASE PROGRESSION; DNA DAMAGE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; HUMANS; MUTATION; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84928938446     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2014.12.007     Document Type: Review

References (79)

1. A. Di Ieva, F. Rotondo, and L.V. Syro Aggressive pituitary adenomas-diagnosis and emerging treatments Nat Rev Endocrinol 10 2014 423 435
2. A.K. Annamalai, A.F. Dean, and N. Kandasamy Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature Pituitary 15 2012 276 287
3. A. Colao, L.F. Grasso, and R. Pivonello Therapy of aggressive pituitary tumors Expert Opin Pharmacother 12 2011 1561 1570
4. K. Kovacs, E. Horvath, and L.V. Syro Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings Hum Pathol 38 2007 185 189
5. O. Moshkin, L.V. Syro, and B.W. Scheithauer Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy Hormones 10 2011 162 167
6. G. Raverot, N. Sturm, and F. de Fraipont Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience J Clin Endocrinol Metab 95 2010 4592 4599
7. G.A. Kaltsas, P. Nomikos, and G. Kontogeorgos Clinical review: diagnosis and management of pituitary carcinomas J Clin Endocrinol Metab 90 2005 3089 3099
8. R.L. Fine, A.P. Gulati, and B.A. Krantz Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience Cancer Chemother Pharmacol 71 2013 663 670
9. C.E. Fadul, A.L. Kominsky, and L.P. Meyer Long-term response of pituitary carcinoma to temozolomide. Report of two cases J Neurosurg 105 2006 621 626
10. B.C. Whitelaw, D. Dworakowska, and N.W. Thomas Temozolomide in the management of dopamine agonist-resistant prolactinomas Clin Endocrinol (Oxf) 76 2012 877 886
11. S. Lim, H. Shahinian, and M.M. Maya Temozolomide: a novel treatment for pituitary carcinoma Lancet Oncol 7 2006 518 520
12. V.J. Moyes, G. Alusi, and H.I. Sabin Treatment of Nelson's syndrome with temozolomide Eur J Endocrinol 160 2009 115 119
13. L.V. Syro, L.D. Ortiz, and B.W. Scheithauer Treatment of pituitary neoplasms with temozolomide: a review Cancer 117 2011 454 462
14. M.F. Stevens, J.A. Hickman, and S.P. Langdon Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine Cancer Res 47 1987 5846 5852
15. O. Fodstad, S. Aamdal, and A. Pihl Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas Cancer Res 45 1985 1778 1786
16. J.A. Hickman, M.F. Stevens, and N.W. Gibson Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent Cancer Res 45 1985 3008 3013
17. L.J. Fairbairn, N. Chinnasamy, and L.S. Lashford Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide Cancer Gene Ther 7 2000 233 239
18. G.U. Baig, and M.F. Stevens Antitumour imidazotetrazines. Part 12. Reactions of mitozolomide and its 3-alkyl congeners with oxygen, nitrogen, halogen, and carbon nucleophiles J Chem Soc Perkin Trans 1 1987 665 670
19. L.L. Tsang, C.P. Quarterman, and A. Gescher Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide Cancer Chemother Pharmacol 27 1991 342 346
20. J.L. Villano, T.E. Seery, and L.R. Bressler Temozolomide in malignant gliomas: current use and future targets Cancer Chemother Pharmacol 64 2009 647 655
21. E.S. Newlands, M.F. Stevens, and S.R. Wedge Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 1997 35 61
22. E.S. Newlands, G.R. Blackledge, and J.A. Slack Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856) Br J Cancer 65 1992 287 291
23. S.D. Baker, M. Wirth, and P. Statkevich Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer Clin Cancer Res 5 1999 309 317
24. J. Brennand, and G.P. Margison Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferase gene Proc Natl Acad Sci USA 83 1986 6292 6296
25. K.A. van Nifterik, J. van den Berg, and W.F. van der Meide Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide Br J Cancer 103 2010 29 35
26. J. Zhang, M.F. Stevens, and T.D. Bradshaw Temozolomide: mechanisms of action, repair and resistance Curr Mol Pharmacol 5 2012 102 114
27. K. Kovacs, B.W. Scheithauer, and M. Lombardero MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy Acta Neuropathol 115 2008 261 262
28. A.I. McCormack, K.L. McDonald, and A.J. Gill Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours Clin Endocrinol (Oxf) 71 2009 226 233
29. S. Mohammed, K. Kovacs, and W. Mason Use of temozolomide in aggressive pituitary tumors: case report Neurosurgery 64 2009 E773 E774 [discussion E774]
30. I.F. Pollack, R.L. Hamilton, and R.W. Sobol O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort J Clin Oncol 24 2006 3431 3437
31. H.S. Friedman, R.E. McLendon, and T. Kerby DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma J Clin Oncol 16 1998 3851 3857
32. M. Esteller, J. Garcia-Foncillas, and E. Andion Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 2000 1350 1354
33. M. Esteller, S.R. Hamilton, and P.C. Burger Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Res 59 1999 793 797
34. M. Esteller, M. Toyota, and M. Sanchez-Cespedes Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis Cancer Res 60 2000 2368 2371
35. X.C. Qian, and T.P. Brent Methylation hot spots in the 5′ flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene Cancer Res 57 1997 3672 3677
36. G.S. Watts, R.O. Pieper, and J.F. Costello Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene Mol Cell Biol 17 1997 5612 5619
37. M.S. Bobola, S.H. Tseng, and A. Blank Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin Clin Cancer Res 2 1996 735 741
38. A.I. McCormack, J.A. Wass, and A.B. Grossman Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status Eur J Clin Invest 41 2011 1133 1148
39. A. McCormack, W. Kaplan, and A.J. Gill MGMT expression and pituitary tumours: relationship to tumour biology Pituitary 16 2013 208 219
40. F. Salehi, B.W. Scheithauer, and K. Kovacs O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas Neurosurgery 70 2012 491 496 [discussion 496]
41. Q. Lau, B. Scheithauer, and K. Kovacs MGMT immunoexpression in aggressive pituitary adenoma and carcinoma Pituitary 13 2010 367 379
42. F. Salehi, B.W. Scheithauer, and V.J. Moyes Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome Endocr Pathol 21 2010 227 229
43. M.J. Bello, J.M. De Campos, and A. Isla Promoter CpG methylation of multiple genes in pituitary adenomas: frequent involvement of caspase-8 Oncol Rep 15 2006 443 448
44. S.L. Asa, and S. Ezzat The pathogenesis of pituitary tumours Nat Rev Cancer 2 2002 836 849
45. L.V. Syro, H. Uribe, and L.C. Penagos Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm Clin Endocrinol (Oxf) 65 2006 552 553
46. L.D. Ortiz, L.V. Syro, and B.W. Scheithauer Temozolomide in aggressive pituitary adenomas and carcinomas Clinics (Sao Paulo) 67 2012 119 123
47. L.V. Syro, B.W. Scheithauer, and L.D. Ortiz Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma Hormones (Athens) 8 2009 303 306
48. I.S. Ciric Pituitary carcinoma World Neurosurg 80 2013 e147 e149
49. H.H. Lee, S.H. Hung, and T.M. Tseng Undifferentiated carcinoma of the pituitary gland: a case report and review of the literature Oncol Lett 7 2014 778 780
50. B.T. Ragel, and W.T. Couldwell Pituitary carcinoma: a review of the literature Neurosurg Focus 16 2004 E7
51. R.F. Cornell, D.F. Kelly, and G. Bordo Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiency Case Rep Endocrinol 2013 2013 675298
52. P.J. Pernicone, B.W. Scheithauer, and T.J. Sebo Pituitary carcinoma: a clinicopathologic study of 15 cases Cancer 79 1997 804 812
53. C. Dai, B. Zhang, and X. Liu Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways Int J Cancer 133 2013 1982 1993
54. J. Iba-Ba, R.B. Ibouili, and J.B. Kombila Cerebral symptomatic toxoplasmosis treated by sulfadoxine/pyrimethamine treatment. About 6 patients Therapie 63 2008 71 72
55. T. Seboxa, P. Mao, and N. Pinchouk Artemether-Lumefantrine (Coartem) and artesunate with sulfadoxine-pyrimethamine therapeutic efficacy in the treatment of uncomplicated malaria at Gilgel Gibe II (GGII) South-Western Ethiopia Ethiop Med J 48 2010 285 291
56. M. Murakami, A. Mizutani, and S. Asano A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report Neurosurgery 68 2011 E1761 E1767 [discussion E1767]
57. L. Liu, S. Markowitz, and S.L. Gerson Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea Cancer Res 56 1996 5375 5379
58. R. Pepponi, G. Marra, and M.P. Fuggetta The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin J Pharmacol Exp Ther 304 2003 661 668
59. D.P. Cahill, K.K. Levine, and R.A. Betensky Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment Clin Cancer Res 13 2007 2038 2045
60. C. Hunter, R. Smith, and D.P. Cahill A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy Cancer Res 66 2006 3987 3991
61. S.A. Nguyen, O.D. Stechishin, and H.A. Luchman Novel MSH6 mutations in treatment-naive glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation Clin Cancer Res 20 2014 4894 4903
62. A. Matsuno, M. Murakami, and K. Hoya Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide Med Mol Morphol 47 2014 1 7
63. M.W. Saif, K. Kaley, and M. Brennan A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy JOP 14 2013 498 501
64. M.S. Thearle, P.U. Freda, and J.N. Bruce Temozolomide (Temodar(R)) and capecitabine (Xeloda(R)) treatment of an aggressive corticotroph pituitary tumor Pituitary 14 2011 418 424
65. A.P. Gulati, B. Krantz, and R.A. Moss Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature Oncology 84 2013 127 134
66. E.A. Garelnabi, D. Pletsas, and L. Li Strategy for imidazotetrazine prodrugs with anticancer activity independent of MGMT and MMR ACS Med Chem Lett 3 2012 965 968
67. D. Pletsas, R.T. Wheelhouse, and V. Pletsa Polar, functionalized guanine-O6 derivatives resistant to repair by O6-alkylguanine-DNA alkyltransferase: implications for the design of DNA-modifying drugs Eur J Med Chem 41 2006 330 339
68. F. Rotondo, M. Cusimano, and B.W. Scheithauer Atypical, invasive, recurring Crooke cell adenoma of the pituitary Hormones 11 2012 94 100
69. E. Morin, F. Berthelet, and J. Weisnagel Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly Pituitary 15 2012 97 100
70. P.M. Arnold, D. Ratnasingam, and M.F. O'Neil Pituitary carcinoma recurrent to the lumbar intradural extramedullary space: case report J Spinal Cord Med 35 2012 118 121
71. M. Philippon, I. Morange, and M. Barrie Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment Ann Endocrinol-Paris 73 2012 225 229
72. A. Ersen, L.V. Syro, and L. Penagos Non-uniform response to temozolomide therapy in a pituitary gonadotroph adenoma Can J Neurol Sci 39 2012 683 685
73. B.W. Scheithauer, E. Horvath, and T.W. Abel Pituitary blastoma: a unique embryonal tumor Pituitary 15 2012 365 373
74. L.D. Ortiz, L.V. Syro, and B.W. Scheithauer Anti-VEGF therapy in pituitary carcinoma Pituitary 15 2012 445 449
75. J. Phillips, H.E. East, and S.E. French What causes a prolactinoma to be aggressive or to become a pituitary carcinoma? Hormones 11 2012 477 482
76. H. Morokuma, T. Ando, and T. Hayashida A case of nonfunctioning pituitary carcinoma that responded to temozolomide treatment Case Reports in Endocrinology 2012 2012 645914
77. I. Zemmoura, A. Wierinckx, and A. Vasiljevic Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management Pituitary 16 2013 515 522
78. M. Batisse, G. Raverot, and S. Maqdasy Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide Cancer investigation. 31 2013 190 196
79. B.E. Zacharia, A.P. Gulati, and J.N. Bruce High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series Neurosurgery 74 2014 E447 E455 [discussion E55]